Stock Events

Stock Events

Nanoform Finland 

€0.47
0
-€0.01-1.58% Today

Statistics

Day High
0.48
Day Low
0.47
52W High
1.24
52W Low
0.41
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

19MayExpected
Q4 2025
Next
-0.06
-0.05
-0.03
-0.02
Expected EPS
-0.049304837064999996
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 4YL.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap276.38B
Merck KGaA operates in the healthcare sector, offering a range of specialty chemicals, materials, and services for pharmaceutical manufacturing that overlap with Nanoform's nanoparticle engineering for drug development.
DuPont de Nemours
DD
Mkt Cap18.99B
DuPont de Nemours, Inc. offers a variety of materials and solutions for the pharmaceutical industry, including drug delivery technologies that compete with Nanoform's offerings.
Pfizer
PFE
Mkt Cap153.59B
Pfizer Inc., as a large pharmaceutical company, invests in drug delivery and formulation technologies, potentially competing with Nanoform's innovative nanoparticle solutions.
Astrazeneca
AZN.LSE
Mkt Cap216.43B
Johnson & Johnson
JNJ
Mkt Cap547.64B
Johnson & Johnson, through its pharmaceutical division Janssen, develops and manufactures drugs that may utilize technologies competing with Nanoform's nanoparticle engineering.
GSK
GSK.LSE
Mkt Cap80.64B
Novo Nordisk
NVO
Mkt Cap182.6B
Novo Nordisk A/S focuses on drug delivery systems for its diabetes and obesity care products, which could compete with Nanoform's nanoparticle formulation technologies.

About

Nanoform Finland Oyj engages in the provision of nanotechnology and drug particle engineering services for the pharma and biotech industries in Europe and the United States. The company provides nanoforming technologies, formulation, and analytical services, including controlled expansion of supercritical solutions technology that enables the creation of active pharmaceutical ingredients (API) nanoparticles directly from solution; biological nanoforming technology; and flexible dosage forms of nanoformed drug substances. It also offers STARMAP, an online platform to pick winners among candidate molecules for CESS powered nanoforming. The company was founded in 2008 and is headquartered in Helsinki, Finland.
Show more...
CEO
Mr. Albert Alexander Haeggstrom
Employees
171
Country
Finland
ISIN
FI4000330972

Listings

ST
SE
NANOFS.ST
STU
DE
4YL.STU
MU
DE
4YL.MU
HE
FI
NANOFH.HE

0 Comments

Share your thoughts

FAQ

What is Nanoform Finland stock price today?▼
The current price of 4YL.STU is €0.47 EUR — it has decreased by -1.58% in the past 24 hours. Watch Nanoform Finland stock price performance more closely on the chart.
What is Nanoform Finland stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Nanoform Finland stocks are traded under the ticker 4YL.STU.
Is Nanoform Finland stock price growing?▼
4YL.STU stock has fallen by -7.43% compared to the previous week, the month change is a -20.09% fall, over the last year Nanoform Finland has showed a -52.1% decrease.
When is the next Nanoform Finland earnings date?▼
Nanoform Finland is going to release the next earnings report on May 19, 2026.
What were Nanoform Finland earnings last quarter?▼
4YL.STU earnings for the last quarter are -0.02 EUR per share, whereas the estimation was -0.06 EUR resulting in a +69.23% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Nanoform Finland have?▼
As of April 29, 2026, the company has 171 employees.
In which sector is Nanoform Finland located?▼
Nanoform Finland operates in the Health & Wellness sector.
When did Nanoform Finland complete a stock split?▼
Nanoform Finland has not had any recent stock splits.
Where is Nanoform Finland headquartered?▼
Nanoform Finland is headquartered in Helsinki, Finland.